CN107001357A - 用作人免疫缺陷病毒复制抑制剂的咪唑并[1,2‑a]吡啶衍生物 - Google Patents

用作人免疫缺陷病毒复制抑制剂的咪唑并[1,2‑a]吡啶衍生物 Download PDF

Info

Publication number
CN107001357A
CN107001357A CN201580058209.6A CN201580058209A CN107001357A CN 107001357 A CN107001357 A CN 107001357A CN 201580058209 A CN201580058209 A CN 201580058209A CN 107001357 A CN107001357 A CN 107001357A
Authority
CN
China
Prior art keywords
alkyl
hiv
mmol
phenyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580058209.6A
Other languages
English (en)
Chinese (zh)
Inventor
B.N.奈杜
T.P.康诺利
K.J.伊斯特曼
K.皮斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54064588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107001357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of CN107001357A publication Critical patent/CN107001357A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580058209.6A 2014-08-27 2015-08-25 用作人免疫缺陷病毒复制抑制剂的咪唑并[1,2‑a]吡啶衍生物 Pending CN107001357A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462042300P 2014-08-27 2014-08-27
US62/042300 2014-08-27
PCT/US2015/046648 WO2016033009A1 (en) 2014-08-27 2015-08-25 Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
CN107001357A true CN107001357A (zh) 2017-08-01

Family

ID=54064588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580058209.6A Pending CN107001357A (zh) 2014-08-27 2015-08-25 用作人免疫缺陷病毒复制抑制剂的咪唑并[1,2‑a]吡啶衍生物

Country Status (13)

Country Link
US (1) US10065953B2 (enExample)
EP (1) EP3186254B1 (enExample)
JP (1) JP2017526748A (enExample)
KR (1) KR20170045308A (enExample)
CN (1) CN107001357A (enExample)
AU (1) AU2015306779B2 (enExample)
BR (1) BR112017003663A2 (enExample)
CA (1) CA2958591A1 (enExample)
CL (1) CL2017000428A1 (enExample)
IL (1) IL250561A0 (enExample)
RU (1) RU2017107715A (enExample)
WO (1) WO2016033009A1 (enExample)
ZA (1) ZA201701214B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232562A (zh) * 2018-10-24 2019-01-18 康化（上海）新药研发有限公司 一种7-氮杂吲哚-5-氯-6-羧酸的合成方法
CN113195475A (zh) * 2018-10-24 2021-07-30 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015174511A1 (ja) 2014-05-16 2015-11-19 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
TWI700284B (zh) 2015-05-29 2020-08-01 日商塩野義製藥股份有限公司 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
US12421235B2 (en) 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459183A (zh) * 2009-05-15 2012-05-16 吉联亚科学股份有限公司 人类免疫缺陷病毒复制的抑制剂
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633200B2 (en) * 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP5918848B2 (ja) * 2011-04-21 2016-05-18 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール化合物およびその薬学的使用
US8987250B2 (en) * 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
EP2970273B1 (en) * 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459183A (zh) * 2009-05-15 2012-05-16 吉联亚科学股份有限公司 人类免疫缺陷病毒复制的抑制剂
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232562A (zh) * 2018-10-24 2019-01-18 康化（上海）新药研发有限公司 一种7-氮杂吲哚-5-氯-6-羧酸的合成方法
CN113195475A (zh) * 2018-10-24 2021-07-30 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂

Also Published As

Publication number Publication date
CA2958591A1 (en) 2016-03-03
JP2017526748A (ja) 2017-09-14
IL250561A0 (en) 2017-03-30
ZA201701214B (en) 2019-07-31
CL2017000428A1 (es) 2017-08-18
US20180222901A1 (en) 2018-08-09
US10065953B2 (en) 2018-09-04
RU2017107715A (ru) 2018-09-27
KR20170045308A (ko) 2017-04-26
AU2015306779B2 (en) 2017-11-02
EP3186254B1 (en) 2019-03-06
EP3186254A1 (en) 2017-07-05
RU2017107715A3 (enExample) 2019-03-04
WO2016033009A1 (en) 2016-03-03
AU2015306779A1 (en) 2017-03-16
BR112017003663A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
CN105189503B (zh) 人免疫缺陷病毒复制的抑制剂
US9006235B2 (en) Inhibitors of human immunodeficiency virus replication
CN107001357A (zh) 用作人免疫缺陷病毒复制抑制剂的咪唑并[1,2‑a]吡啶衍生物
CN105189511B (zh) 人免疫缺陷病毒复制的抑制剂
US9034882B2 (en) Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) Inhibitors of human immunodeficiency virus replication
CN105008358B (zh) 人免疫缺陷病毒复制的抑制剂
CN105189510B (zh) 人免疫缺陷病毒复制的抑制剂
CN108137552A (zh) 作为人免疫缺陷病毒复制的抑制剂的5-(n-稠合三环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
US9932356B2 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
JP2018520162A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CN108137553A (zh) 作为人免疫缺陷病毒复制的抑制剂的5-(n-[6,5]-稠合双环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
US9944656B2 (en) Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
JP2019515939A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CN107771177A (zh) 作为人类免疫缺陷病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物
US9932353B2 (en) Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
JP2018519348A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2018522924A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのイミダゾピリジン大環状化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801